Back to home
CLINICAL SIGNALMarch 18, 2026·7 min read
Arvinas PROTAC Achieves >50% LRRK2 Degradation in Parkinson's Patients
Phase 1 data for ARV-102 shows meaningful target engagement in cerebrospinal fluid after 28 days, marking the first clinical proof-of-concept for protein degradation in neurodegenerative disease.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.